According to the statement made from Italy, it was reported that the use of the single-dose Johnson & Johnson Covid-19 vaccine, which was decided to be stopped in the USA due to blood clot problems, was suspended in the country.
While it was stated that the use of 184 thousand Johnson & Johnson Covid-19 vaccines in the country was suspended, Italy’s Covid special commissioner announced that the first vaccine shipment from the US company reached Italy, but will not be distributed to regional centers for now.
Vaccine authorities in Europe adopted different approaches after the Centers for Disease Control and Prevention (CDC) and the US Food and Drug Administration (FDA), two of the most important health organizations in the USA, received advice on a vaccine suspension.
CONTINUE TO USE BELGIUM AND FRANCE
While Greece puts the use of the single-dose Johnson & Johnson Covid-19 vaccine on hold, Belgium and France said they will continue with the vaccine.
The European Medicines Agency (EMA) said it expects to publish a recommendation on the Johnson & Johnson Covid-19 vaccine next week.
Italy’s vaccine authorities have previously stated that they can limit the use of the vaccine to people over the age of 60.
It was hoped that the single-dose Johnson & Johnson Covid-19 vaccine would accelerate the slow-moving vaccine campaign in Italy, following the emergence of supply delays and blood clot problems detected in the AstraZeneca vaccine.
‘MAY HAVE DESTRUCTIVE EFFECT’
While the use of the AstraZeneca vaccine was suspended for three days in Italy in mid-March, it is currently only recommended for people over 60.
“Possible age restrictions on the Johnson & Johnson vaccine could have a devastating effect, as in the AstraZeneca case,” said Alessio D’Amato, head of health in the Lazio region around Rome. “There is a risk of serious damage to the vaccination campaign.”